Literature DB >> 17213835

Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA.

Marc S Weinberg1, Abdullah Ely, Samantha Barichievy, Carol Crowther, Steven Mufamadi, Sergio Carmona, Patrick Arbuthnot.   

Abstract

Activating RNA interference to achieve specific gene silencing has shown promise for the development of RNA-based treatment of chronic hepatitis B virus (HBV) infection. To further this approach, we assessed the efficacy of expressed long hairpin RNAs (lhRNAs) that target the conserved HBx open reading frame of HBV. As substrates for Dicer, lhRNAs have the potential to generate multiple short interfering RNAs (siRNAs) to enable simultaneous targeting of different sites. Two U6 Pol III vectors were constructed that encode anti-HBV lhRNAs with a 62 base pair stem sequence containing multiple G:U pairings. Assessment in transfected cultured cells and also in vivo using the murine hydrodynamic injection model showed that one of the lhRNA vectors (lhRNA 1) diminished markers of virus replication by 70-90% without evidence of interferon response induction. Greatest silencing efficacy was observed for targets that are complementary to sequences located at the base of the hairpin stem and this correlated with a higher concentration of siRNAs derived from this region of the lhRNA. Although lhRNA 1 has the advantage of targeting a greater viral sequence, incomplete cellular processing may result in unequal silencing across the span of the viral target RNA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213835     DOI: 10.1038/sj.mt.6300077

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

Review 1.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

2.  Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses.

Authors:  D Ivacik; A Ely; N Ferry; P Arbuthnot
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

Review 3.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

4.  A direct comparison of strategies for combinatorial RNA interference.

Authors:  Luke S Lambeth; Nick J Van Hateren; Stuart A Wilson; Venugopal Nair
Journal:  BMC Mol Biol       Date:  2010-10-11       Impact factor: 2.946

5.  Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors.

Authors:  Sheena Saayman; Patrick Arbuthnot; Marc S Weinberg
Journal:  Nucleic Acids Res       Date:  2010-06-04       Impact factor: 16.971

Review 6.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection.

Authors:  Yong Chen; Ram I Mahato
Journal:  J Drug Target       Date:  2008-02       Impact factor: 5.121

8.  Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference.

Authors:  Karin Jasmijn von Eije; Olivier ter Brake; Ben Berkhout
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

9.  RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs.

Authors:  Lindsey L Snyder; Iqbal Ahmed; Laura F Steel
Journal:  Nucleic Acids Res       Date:  2009-08-13       Impact factor: 16.971

10.  Combinatorial RNAi against HIV-1 using extended short hairpin RNAs.

Authors:  Ying Poi Liu; Karin Jasmijn von Eije; Nick C T Schopman; Jan-Tinus Westerink; Olivier ter Brake; Joost Haasnoot; Ben Berkhout
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.